Myosin X Inhibitors
Myosin X inhibitors constitute a diverse group of compounds designed to modulate the activity of Myosin X, a molecular motor involved in actin-based cellular processes. Blebbistatin, a myosin II ATPase inhibitor, impacts Myosin X indirectly by altering actin dynamics through inhibition of myosin II, influencing the overall cytoskeletal organization. Similarly, CK-666 and CK-869, Arp2/3 complex inhibitors, modulate actin dynamics and may indirectly affect Myosin X by disrupting actin filament assembly and cytoskeletal organization. Inhibition of the RhoA/ROCK signaling pathway by Y-27632 indirectly influences Myosin X by altering actin cytoskeletal dynamics. Jasplakinolide, while not a direct inhibitor, induces actin polymerization and may impact Myosin X by influencing actin dynamics and cytoskeletal organization. ML-7, a myosin light chain kinase (MLCK) inhibitor, modulates Myosin X through changes in myosin regulatory light chain phosphorylation and actin-myosin interactions.
Compounds like Latrunculin A and Cytochalasin D directly inhibit actin polymerization, influencing Myosin X by altering the organization of actin filaments and impacting its ability to move along the cytoskeleton. SMIFH2 and CK-548, formin inhibitors, modulate formin-mediated actin polymerization, impacting Myosin X by altering actin dynamics and cytoskeletal organization. Brefeldin A, an inhibitor of small GTPases, modulates vesicular trafficking and actin dynamics, impacting Myosin X through alterations in the organization of actin filaments and cellular cytoskeletal organization. NSC23766, a Rac1 inhibitor, modulates Rac1 signaling and may influence Myosin X through changes in actin dynamics associated with cell migration and adhesion. In conclusion, Myosin X inhibitors, whether direct or indirect, provide valuable tools for researchers to selectively modulate Myosin X and investigate its role in various cellular processes. This diverse array of compounds allows for a nuanced understanding of the intricate regulatory networks governed by Myosin X in the context of actin dynamics and cytoskeletal organization.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Inhibitor of myosin II ATPase activity. While primarily targeting myosin II, it may indirectly impact Myosin X through alterations in actin dynamics and cellular cytoskeletal organization. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
Arp2/3 complex inhibitor. Modulates actin dynamics by inhibiting the Arp2/3 complex, potentially influencing Myosin X through changes in actin filament assembly and cytoskeletal organization. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor. Affects RhoA/ROCK signaling, potentially impacting Myosin X through alterations in actin cytoskeletal dynamics and cellular processes associated with cell migration and adhesion. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Actin polymerization inducer. While not a direct inhibitor, it induces actin polymerization and may indirectly modulate Myosin X by influencing actin dynamics and cytoskeletal organization. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Myosin light chain kinase (MLCK) inhibitor. Modulates MLCK activity, potentially impacting Myosin X through changes in myosin regulatory light chain phosphorylation and actin-myosin interactions. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Actin polymerization inhibitor. Disrupts actin dynamics, potentially influencing Myosin X by altering the organization of actin filaments and impacting the molecular motor's ability to move along the cytoskeleton. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
Formin inhibitor. Modulates formin-mediated actin polymerization, potentially impacting Myosin X by altering the dynamics of actin filaments and the cellular cytoskeleton. | ||||||
CK-869 | 388592-44-7 | sc-507274 | 5 mg | $163.00 | ||
Arp2/3 complex inhibitor. Similar to CK-666, it modulates actin dynamics by inhibiting the Arp2/3 complex, potentially influencing Myosin X through changes in actin filament assembly and cytoskeletal organization. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Actin polymerization inhibitor. Disrupts actin filament assembly, potentially influencing Myosin X by altering the organization of actin filaments and impacting the molecular motor's ability to move along the cytoskeleton. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Inhibitor of small GTPases (e.g., Arf1). Modulates vesicular trafficking and actin dynamics, potentially impacting Myosin X through alterations in the organization of actin filaments and cellular cytoskeletal organization. | ||||||